1. Viking Therapeutics' stock has dropped 25% despite Phase 2 promising results for VK2735 due to competition in the obesity treatment market; 2. Viking's financial health is strong with over $50 million in cash and $880 million in short-term investments; 3. The obesity treatment market is dominated by Eli Lilly and Novo Nordisk, challenging Viking's differentiation and market share gain.